Envivo Pharmaceuticals, Inc.
Records under this name other than patents Envivo Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Envivo Pharmaceuticals, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,273,044 | Crystalline Form of (R)-7-Chloro-N-(QUINUCLIDIN-3-YL)BENZO[B]THIOPHENE-2-Carboxamide Hydrochloride Monohydrate Formerly held Lapsed on the fee record Ended Mar 1, 2024 · High confidence | Lapsed on the fee record | Ended Mar 1, 2024 | High confidence |
| US 9,108,961 | Crystalline Form of (R)-7-Chloro-N-(Quinuclidin-3-YL)benzo[B]thiophene-2-Carboxamide Hydrochloride Monohydrate Lapsed on the fee record Ended Aug 18, 2023 · High confidence | Lapsed on the fee record | Ended Aug 18, 2023 | High confidence |
| US 8,815,933 | Treatment of Cognitive Disorders with (R)-7-Chloro-N-(QUINUCLIDIN-3-YL)BENZO[B]THIOPHENE-2-Carboxamide and Pharmaceutically Acceptable Salts Thereof Formerly held Lapsed on the fee record Ended Aug 26, 2022 · Medium confidence | Lapsed on the fee record | Ended Aug 26, 2022 | Medium confidence |
| US 8,710,227 | Crystalline Form of (R)-7-Chloro-N-(QUINUCLIDIN-3-YL)BENZO[B]THIOPHENE-2-Carboxamide Hydrochloride Monohydrate Formerly held Lapsed on the fee record Ended Apr 29, 2022 · High confidence | Lapsed on the fee record | Ended Apr 29, 2022 | High confidence |
| US 8,642,638 | Treatment of Cognitive Disorders with (R)-7-Chloro-N-(QUINUCLIDIN-3-YL)BENZO[B]THIOPHENE-2-Carboxamide and Pharmaceuticall Acceptable Salts Thereof Formerly held Lapsed on the fee record Ended Feb 4, 2022 · Medium confidence | Lapsed on the fee record | Ended Feb 4, 2022 | Medium confidence |
| US 8,569,354 | Treatment of Cognitive Disorders with (R)-7-Chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-Carboxamide and Pharmaceutically Acceptable Salts Thereof Formerly held Lapsed on the fee record Ended Oct 29, 2021 · Medium confidence | Lapsed on the fee record | Ended Oct 29, 2021 | Medium confidence |
| US 8,466,148 | 1,2-Disubstituted Heterocyclic Compounds Formerly held Lapsed on the fee record Ended Jun 18, 2021 · High confidence | Lapsed on the fee record | Ended Jun 18, 2021 | High confidence |
| US 8,399,452 | DIBENZO[B,F][1,4]OXAZEPIN-11-YL-N-HYDROXYBENZAMIDES as Hdac Inhibitors Formerly held Lapsed on the fee record Ended Mar 19, 2021 · High confidence | Lapsed on the fee record | Ended Mar 19, 2021 | High confidence |
| US 9,550,767 | Crystalline Form of (R)-7-Chloro-N-(Quinuclidin-3-YL)benzo[B]thiophene-2-Carboxamide Hydrochloride Monohydrate Formerly held Lapsed on the fee record Ended Jan 24, 2021 · High confidence | Lapsed on the fee record | Ended Jan 24, 2021 | High confidence |
| US 9,540,380 | Imidazotriazinone Compounds Formerly held Lapsed on the fee record Ended Jan 10, 2021 · Medium confidence | Lapsed on the fee record | Ended Jan 10, 2021 | Medium confidence |